New innovative cancer therapies to help 132,000 people diagnosed each year with Melanoma

The Global Structure of Melanoma R&D is one of the most comprehensive and up to date information sources currently available in the melanoma R&D arena. Information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed.

Malignant melanoma is the deadliest form of skin cancer and is diagnosed in approximately 132,000 people worldwide each year (2000 data). The incidence of melanoma is increasing at a rate of 3-5% per year. According to the American Cancer Society, the lifetime risk of malignant melanoma in the U.S. has risen from 1/1,500 people in 1935 to 1/74 people in 2000, with a forecast of 1/50 people by 2005. Melanoma currently affects nearly 200,000 people and in 1997 there were an estimated 40,300 new cases and 7,300 deaths. While melanoma is 85-90% curable if identified and treated in its earliest stages, melanoma that has metastasized is deadly. Even after surgical removal, the five-year survival rate for metastatic melanoma is only 20-50%.

This exciting new report details Information on more than 140 companies active in melanoma R&D, Information on more than 230 industry related melanoma projects, Data from 140 clinical trials and information on more than 70 preclinical projects.
Results are presentes as therapies given, the therapeutic effect as well as the mechanism of action.

For a complete index of this report click on http://www.researchandmarkets.com/reports/39944

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com